Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Leukemia and Lymphoma (SAGAN Trial)
SAGAN Trial Summary
This trial is testing a new cancer treatment combining two existing methods: T cells and antibodies. Researchers hope that the combination will be stronger than either method alone in fighting the cancer.
SAGAN Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSAGAN Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SAGAN Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I agree to use effective birth control during and for 6 months after the study.I am currently on antibiotics for an active infection.I have no cancer history, except for certain skin, breast, or cervix cancers treated over 2 years ago.My tumor is CD19 positive.I am not on experimental drugs but can be on PD1/PDL1 inhibitors.My tumor is located where it could block my airway if it grows.I do not have an active HIV or HTLV infection.I have B-cell lymphoma or leukemia and cannot complete standard therapy or need a stem cell transplant.I am 75 years old or younger and among the first 3 adults to join the study.My kidneys are functioning well.My oxygen level is above 90% without needing extra oxygen.I am mostly independent and can care for myself.I have recovered from the side effects of my last chemotherapy, and it's been over a week.My treatment involves T cells from my blood or an identical twin that target CD19.I have B-cell lymphoma or leukemia and cannot complete standard therapy or need a stem cell transplant.My tumor is CD19 positive.I am 75 years old or younger and among the first 3 adults to join the study.
- Group 1: Dose Escalation: CD19 CAR T Cells for B-cell ALL
- Group 2: Dose Expansion: CD19 CAR T Cells for B-cell ALL
- Group 3: Dose Escalation: CD19 CAR T Cells for B-cell NHL/CLL
- Group 4: Dose Expansion: CD19 CAR T Cells for B-cell NHL/CLL
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor currently looking for participants?
"Clinicaltrials.gov reveals that this medical study is currently enrolling patients, with the initial listing being posted on February 1st 2014 and updated most recently on January 11th 2022."
In what medical circumstances is Cyclophosphamide typically utilized?
"Primarily used to combat multiple sclerosis, cyclophosphamide has also been prescribed in cases of mixed-cell type lymphoma, leukemia, myelocytic, acute and retinoblastoma."
Has the Federal Drug Administration sanctioned Cyclophosphamide?
"The safety of cyclophosphamide, which is being evaluated in a Phase 1 setting, has been assessed as low relative to other drugs with only limited evidence vouching for its efficacy and security."
Could you elucidate on previous investigations involving Cyclophosphamide?
"Presently, 889 clinical trials are underway in an effort to further understand Cyclophosphamide. Of these studies, 161 have progressed as far as Phase 3 and boast 28443 locations of operation with Philadelphia, Pennsylvania being the most prevalent."
How many participants are included in this medical experiment?
"Affirmative. According to clinicaltrials.gov, this trial is currently in the process of recruiting patients since it was posted on February 1st 2014 and recently updated on January 11th 2022. The goal is to secure 64 participants from two sites for the study."
Share this study with friends
Copy Link
Messenger